SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

David Bitto

Senior Scientist

David Bitto

David supports a range of vaccine pipelines with molecular biology-related work.

He joined SpyBiotech in May 2022 from the School of Cellular and Molecular Medicine at the University of Bristol, where he worked on the cell biology of influenza virus infection. David has over a decade of experience in virus-host interactions with a particular expertise in arthropod-borne viruses, but he has also developed an interest in Intellectual Property.

David holds a doctorate in Clinical Medicine from the Nuffield Department of Clinical Medicine at the University of Oxford, where he established and developed the first in vitro model system for phlebovirus (order Bunyavirales) membrane fusion, the latter of which is an important checkpoint during viral host cell entry.

Back to team

Read more about our pipeline and the diseases we are working to eradicate.

Our Pipeline